MINERAL AND BONE DISORDERS IN CHRONIC KIDNEY DISEASE PEDRAM.AHMADPOOR SHAHID BEHESHTI MEDICAL UNIVERSITY.

Slides:



Advertisements
Similar presentations
LINEE GUIDA, KDIGO E DIALISI PERITONEALE
Advertisements

Ca++, PO4, PTH & VIT D Calcium, Phosphorus & Vitamin D
Bone Disease in Renal Failure Dr Anne Kleinitz and Dr Cherelle Fitzclarence
Regulation of calcitonin secretion Elevation of blood calcium –Response greater in male –Affected by age Declines as one ages Secretion by GI tract –Gastrin.
Nutrition Therapy and Dialysis Melinda S. Leone, MS, RD St. Joseph's Regional Medical Center Division of Nephrology Paterson, NJ 07503
UPDATE ON RENAL BONE DISEASE Dr Jo Taylor July, 2006.
Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
Renal replacement therapy - indications. S. Zmonarski.
West Midlands Guidelines for managing CKD Mineral and Bone Disorders in Haemodialysis Patients
Journal Club EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events – EVOLVE NEJM Dec 2012 Yuvaraj Thangaraj, M.D. Nephrology Fellow Division.
Chronic Renal Failure Niroj Obeyesekere 3 rd year student notes.
A.O.Osp.Riuniti Marche Nord Presidio San Salvatore
Calcium & phosphor disturbance CKD- MBD Dr. Atapour.
Management of hyperphosphataemia of chronic kidny disease Presented by Pharmacist/ Eman Youssif 1.
 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:
This lecture was conducted during the Nephrology Unit Grand Ground by Consultant under Nephrology Division under the supervision and administration of.
Mario Cozzolino, MD, PhD NUOVE ACQUISIZIONI NELLA TERAPIA DELL’IPERPARATIROIDISMO SECONDARIO IN DIALISI PERITONEALE XV CONVEGNO del Gruppo di Studio di.
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Anemia in chronic kidney disease
Calcium & Inorganic phosphate. Calcium Physiological function : Bone mineralization Blood coagulation Important in muscle contraction Affecting enzyme.
PRINCIPLES OF DIALYSIS DR SAAD ALSHOHAIB ASSOCIATE PROFESSOR IN MEDICINE AND NEPHROLOGY KAUH.
Bone and Mineral Disorders in Chronic Kidney Disease
Diseases of the Renal System KNH 413. CKD - Renal Replacement Therapy Hemodialysis (HD) or Peritoneal Dialysis (PD) Type based on underlying kidney disease.
Calcium & phosphorus.
Diabetes and Kidney. Diabetic Kidney Normal Kidney.
Secondary Hyperparathyroidism in Chronic Kidney Disease 2009/11/13 신장내과 R3 이완수.
Adynamic Bone Disease Begins before Dialysis The 25 th Annual Dialysis Conference in Tampa Akihide Tokumoto, M.D. San-in Rosai Hospital, Yonago, Japan.
OUT LINES ■Overview of calcium and phosphate regulation in the extracellular fluid and . plasma ■ Non- Bone physiologic effects of altered calcium and.
Calcium Homeostasis. 99% body calcium in skeleton 0.9 % intracellular 0.1% extracellular 50% bound Mostly albumin (alkalosis) Smaller amount phosphorous.
PTH Calcitonin 10mg% Vitamin D Lecture 52 Ca++ Homeostasis
Chronic Kidney Disease SERVICE 6. Chronic Kidney Disease Stages 4-5 (GFR
Renal Osteodystrophy ( paraclinical evaluation ) Dr. Y. Ataipour Hashemi Nejad Hospital TUMS.
Dietary Issues in Renal Complications Ulrich Wahl, Tamworth, 2010.
Kidney Disease 2 kidneys Each the size of your fist One on each side of your spine Weight 4-6 ounces each Nephron - the basic functioning unit of the.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
Regulation of Potassium K+
Progression of Chronic Kidney Disease
RICKETS DR. MUHAMMAD ABBAS ASSTT. PROFESSOR DEPTT. OF PEDIATRICS SIMS/SERVICES HOSPITAL LAHORE.
AGENTS FOR BONE AND BONE GROWTH : CALCIUM PREPARATIONS.
Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis :A randomized clinical trial Jay.
Renal Nutrition. Kidney Disease 2 kidneys 2 kidneys Each the size of your fist Each the size of your fist One on each side of your spine One on each side.
Calcium, Phosphorus, Magnesium and Related Disorders (By Basil OM Saleh) Objective: 1. Calcium & Phosphorus homeostasis, Hypercalcaemia, and Hypocalcaemia.
CKD Treatment 순천향 대학교병원 신장내과 R3 김재연. Chronic kidney disease (CKD) encompasses a spectrum of different pathophysiologic processes associated with abnormal.
Oral phosphate binders in patients with kidney failure
Dietary restriction inadequate, phosphate still high Calcichew®
Oral Phosphate Binders in Patients with Kidney Failure
CALCIUM Muthana A. Al-Shemeri.
MINERALS IN HUMAN HEALTH
Renal mechanisms for control ECF
The ECHO Observational Study
PARATHYROID AND CALCIUM HOMEOSTASIS
HYPERPHOSPHAT EMIA Group 5. Outlines -Disease manifestation (symptoms,signs), pathogenesis and pathophysiology. -Plan of treatment -Brief detail on pharmacology.
Hormonal control of calcium and phosphate metabolism
CKD–Mineral and Bone Disorder: Core Curriculum 2011
Renal Disease Filtration, glomeruli generate removal ultrafiltrate of the plasma based on size and charge of molecules End products include urea, creatinine,
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
CKD Complications By Alaina Darby.
Bone metabolism and disease in chronic kidney disease
Phosphorus Nutrition and the Treatment of Osteoporosis
CKD–Mineral and Bone Disorder: Core Curriculum 2011
Guidelines American Journal of Kidney Diseases
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Deprescribing Calcium-Based Phosphorus Binders in Dialysis Patients
Volume 66, Pages S25-S32 (September 2004)
Conclusion and Future Direction:
REGULATION OF K,Ca, PHOSPHATE & MAGNISIUM
International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes.
Ionized-to-total magnesium (Mg) and calcium (Ca) ratios are lower in patients on hemodialysis than those in patients not on dialysis. Ionized-to-total.
Diseases of the Renal System
Tamara Isakova, Orlando M. Gutiérrez, Myles Wolf  Kidney International 
Presentation transcript:

MINERAL AND BONE DISORDERS IN CHRONIC KIDNEY DISEASE PEDRAM.AHMADPOOR SHAHID BEHESHTI MEDICAL UNIVERSITY

Normal Bone Metabolic Unit Low turn over bone disease High turn over bone disease mixed

TMV classification OM=Osteomalacia OF=Osteitis fibrosa AD= Adynamic bone disease MUD=Mixed

Mechanism for 2 HPT in CRF Increased intracellular P in remaining proximal tubules  suppression of 1-alpha OHase Increased intracellular P in remaining proximal tubules  suppression of 1-alpha OHase Decreased level of 1,25 D3 starts with GFR<80 Decreased level of 1,25 D3 starts with GFR<80 Increased intracellular P starts earlier than changes in serum P Increased intracellular P starts earlier than changes in serum P

Consequences of 1,25( OH )D3 deficiency Increase in PTH level Increase in PTH level Parathyroid cell proliferation ( VDR) Parathyroid cell proliferation ( VDR) Decreased bone calcemic response to PTH Decreased bone calcemic response to PTH Increased PTH set point,Decreased CaSR Increased PTH set point,Decreased CaSR Hypocalcemia Hypocalcemia

PTH - Calcium set point PTH Ionised Calcium 1.25 mmol/l Normal Uraemia 50%

Causes of decreased 1,25(OH)D3 synthesis in renal failure Phosphate retention and Hyperphosphatemia Phosphate retention and Hyperphosphatemia Renal tissue loss Renal tissue loss Uremic toxins(GSA,Uric acid) Uremic toxins(GSA,Uric acid) FGF-23 FGF-23

Clinical Manifestation of Renal Osteodystrophy Bone pain Bone pain Myopathy and muscle weakness Myopathy and muscle weakness Pruritis Pruritis Metastatic and extraskeletal calcification (vascular –soft tissue) Metastatic and extraskeletal calcification (vascular –soft tissue) Arthritis and Periarthritis Arthritis and Periarthritis Spontaneous tendon rupture Spontaneous tendon rupture

rugger jersey spine

sub-periosteal resorption

AP view looser’s zone frogleg view looser’s zone

Vascular Calcification in ESRD Reprinted from: London, et al. Nephrol Transpl Dial. 2003;18: (London, 2003 p fig.1)

Increased Death Risk in CKD Stage 5 with Elevated Serum Calcium Adapted from Block GA et al. J Am Soc Nephrol. 2004;15:

K/DOQI™ Clinical Practice Guidelines on Bone Metabolism Target Levels CKD Stage 3 CKD Stage 4 CKD Stage 5 (on dialysis) P(mg/dL) * Ca(mg/dL)“Normal”“Normal” ; Hypercalcemia = >10.2 Intact PTH (pg/mL) *

Prevention and Treatment of Renal Osteodystrophy Prevention of Phosphate retention and Hyperphosphatemia Prevention of Phosphate retention and Hyperphosphatemia Treatment of Hypocalcemia Treatment of Hypocalcemia Vit. D analogs Vit. D analogs Calcimimetics Calcimimetics Parathyroidectomy Parathyroidectomy

Phosphate binders Calcium containing Calcium containing CaCO3 CaCO3 Ca acetate (Phoslo) Ca acetate (Phoslo) non calcium containing non calcium containing Renagel,Renvela Renagel,Renvela lanthanum carbonate (Fosrenol) lanthanum carbonate (Fosrenol) Mg Mg Al Al

Al based phosphate binders Aluminium toxicities Aluminium toxicities Bone Bone Neurologic Neurologic hematologic hematologic Calcium based phosphate binders Calcium based phosphate binders

P<5.5 Ca<9.5  Ca containing P binder P<5.5 Ca<9.5  Ca containing P binder P 9.5 no P binder P 9.5 no P binder ( if vascular calc.  non calcium containing P binder) ( if vascular calc.  non calcium containing P binder) P>5.5 Ca 5.5 Ca <9.5  Ca containing P binder if Ca x P <55 if Ca x P <55 P>5.5 Ca >9.5  non Ca containting P binder P>5.5 Ca >9.5  non Ca containting P binder Ca containing P binders must not be used if: Ca containing P binders must not be used if: PTH <150 PTH <150 corrected Ca >10.2 corrected Ca >10.2 P binder elemental Ca >1500 P binder elemental Ca >1500 total elemental Ca >2000 total elemental Ca >2000

A 45 years old man under hemodialysis for 6 years due to chronic GN ( wt =70 kg) A 45 years old man under hemodialysis for 6 years due to chronic GN ( wt =70 kg) Ca = 9.8 mg% Ca = 9.8 mg% P = 5.7 mg% P = 5.7 mg% intact PTH = 600 pg/ml intact PTH = 600 pg/ml albumin =3.7 gr/dl albumin =3.7 gr/dl dialysis 3 x4 h/wk dialysis 3 x4 h/wk What type of bone disease ? How do you manage it How do you manage it

Diet  mg P /d Diet  mg P /d Phosphate binder? Phosphate binder? Types of Phosphate binder? Types of Phosphate binder? Calcium containing Calcium containing CaCO3 CaCO3 Ca acetate (Phoslo) Ca acetate (Phoslo) non calcium containing non calcium containing Renagel,Renvela Renagel,Renvela lanthanum carbonate (Fosrenol) lanthanum carbonate (Fosrenol) Mg Mg Al Al

P>5.5 Ca >9.5  non Ca containting P binder Dose? Dose? Depends on P blood level Depends on P blood level daily removal daily removal daily intake /absorption daily intake /absorption binder potency binder potency

39 mg P will bind to 1 gr CaCO3 39 mg P will bind to 1 gr CaCO3 45 mg P will bind to 1 gr Ca acetate 45 mg P will bind to 1 gr Ca acetate 32 mg to each 400 mg renagel 32 mg to each 400 mg renagel 64 mg to each 800 mg renagel tab 64 mg to each 800 mg renagel tab 15.3 mg to each Al tab 15.3 mg to each Al tab 22.3 mg to 5 ml AlOH mg to 5 ml AlOH3

For each gr protein intake consider 10-12mg P intake For each gr protein intake consider 10-12mg P intake Recommended protein intake in HD=1-1.2 g/kg Recommended protein intake in HD=1-1.2 g/kg 70 x 1.2 = 840 mg /d 70 x 1.2 = 840 mg /d 840 x 60% = 504 mg /d  accumulation 840 x 60% = 504 mg /d  accumulation each dialysis P removal  mg each dialysis P removal  mg CAPD  300 mg/d CAPD  300 mg/d 800 x 3= 2400 mg 800 x 3= 2400 mg 504 x 7 = x 7 = – 2400 = 1128 /7= 160 mg /d ( amount of P that must be bound) 3528 – 2400 = 1128 /7= 160 mg /d ( amount of P that must be bound) 64 mg to each 800 mg renagel tab 64 mg to each 800 mg renagel tab about 3 renagel tab /d about 3 renagel tab /d Ca-P recheck within 1-4 wks PTH q 1-3 months

How many Ca CO3 pills ? 160 mg/39= 4 gr CaCO3 ( 8 tab /d) 160 mg/39= 4 gr CaCO3 ( 8 tab /d) elemental Ca = 4000 mg x40%=1600 mg elemental Ca = 4000 mg x40%=1600 mg Ca containing P binders must not be used if: Ca containing P binders must not be used if: PTH <150 PTH <150 corrected Ca >10.2 corrected Ca >10.2 P binder elemental Ca >1500 P binder elemental Ca >1500 total elemental Ca >2000 total elemental Ca >2000 COMBINATION POLICY COMBINATION POLICY

P<5.5 Ca<9.5  Ca containing P binder P<5.5 Ca<9.5  Ca containing P binder P 9.5 no P binder P 9.5 no P binder ( if vascular calc.  non calcium containing P binder) ( if vascular calc.  non calcium containing P binder) P>5.5 Ca 5.5 Ca <9.5  Ca containing P binder P>5.5 Ca >9.5  non Ca containting P binder P>5.5 Ca >9.5  non Ca containting P binder

Vit D derivatives Vit D derivatives if intact PTH >300 & Ca 300 & Ca <9.5 & P<5.5 & Ca x P <55 Ca x P <55 Corrected Ca >10.2  stop Corrected Ca >10.2  stop Corrected Ca  50% dose reduction Corrected Ca  50% dose reduction corrected Ca rising  dose reduction corrected Ca rising  dose reduction Role of low dose active vitamin D irrespective of parathyroid suppression on overall mortality Role of low dose active vitamin D irrespective of parathyroid suppression on overall mortality

Vitamin D analogs 25(OH) D3 ( calcifediol) 1,25 (OH) D3 (calcitriol, rocaltrol) 1 alpha (OH) D3 ( alphacalcidiol,one alpha) 1alpha (OH) D2 (doxercalciferol, hectoral) 22 oxa 1,25 (OH) D3 (22 oxacalcitriol,maxacalcitol) 19 nor 1,25( OH) D2 (paricalcitol, zemplar) 24,25(OH)D3

Cinacalcet Cinacalcet indicated in all pts with intact PTH >300 and Ca >8.4 indicated in all pts with intact PTH >300 and Ca >8.4 (decrease parathyroidectomy,cardivascular hospitalizations,Fx) (decrease parathyroidectomy,cardivascular hospitalizations,Fx) Hyperphosphatemia is not containdication starting dose 30 mg/d  180 q4wks starting dose 30 mg/d  180 q4wks cinacalcet must not be started if Ca<8.4 cinacalcet must not be started if Ca<8.4 during Tx  Ca <7.4  stop during Tx  Ca <7.4  stop  adding vit d and /calcium if P <  adding vit d and /calcium if P <5.5 So if Ca 300  start with vit.D derivative

28 cinacalcet = 400,000 toman 28 cinacalcet = 400,000 toman Renagel 400 mg= 1980 toman Renagel 400 mg= 1980 toman AlOH3 AlOH3 Increasing dialysis Increasing dialysis parathyroidectomy parathyroidectomy

How can we calculate daily protein intake CRF= 6.25 ( urine urea nitrogen + nonurea nitrogen) + proteinuria if > 5 gr/d CRF= 6.25 ( urine urea nitrogen + nonurea nitrogen) + proteinuria if > 5 gr/d nonurea nitrogen =30mg/kg nonurea nitrogen =30mg/kg

How can we calculate daily protein intake HD (anuric ) HD (anuric ) PCR = x delta BUN PCR = x delta BUN Interval Interval BUN before dialysis = 70 BUN before dialysis = 70 BUN after diaysis = 30 BUN after diaysis = 30 interval =44 interval = x 40= 34/44= 0.78 gr/kg/d 0.86 x 40= 34/44= 0.78 gr/kg/d

Urinary urea nitrogen (g) x 150 anuric PCR+ ——————————————— ID interval (hrs) x weight (kg) Urinary urea nitrogen (g) x 150 anuric PCR+ ——————————————— ID interval (hrs) x weight (kg) PD: PCR = 6.25 x (Urea appearance [0.031x lean body weight, kg]) PD: PCR = 6.25 x (Urea appearance [0.031x lean body weight, kg])